Patterns of infliximab use among Crohn's disease patients in a community setting

Inflammatory Bowel Diseases

Volumn 14, Issue 9, 2008, Pages 1265-1272

  Pressman, Alice R ^a   Hutfless, Susan ^a,b   Velayos, Fernando ^c   Fireman, Bruce ^a   Lewis, James D ^d   Allison, James ^a,c   Abramson, Oren ^a   Herrinton, Lisa J ^a  

^a DIVISION OF RESEARCH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Computerized medical information; Crohn's disease; Health services research; Infliximab; Variation in care

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; COLONOSCOPY; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; DRUG UTILIZATION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; HEALTH SERVICES RESEARCH; HOSPITAL PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; OUTPATIENT; PRIORITY JOURNAL; SEX DIFFERENCE; SIGMOIDOSCOPY; SINGLE DRUG DOSE; UNITED STATES;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CALIFORNIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROHN DISEASE; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 54349090370     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20483     Document Type: Article

References (25)

1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factors alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
2. Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006;23:1127-1136.
3. Hanauer SB, Feagan BD, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359: 1541-1549.
4. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2:912-920.
5. Fiocchi C. Closing fistulas in Crohn's disease - should the accent be on maintenance or safety? N Engl J Med. 2004;350:934-936.
6. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.
7. Deckelbaum L. Dear Doctor Letter. http://www.fda.gov/MedWatch/SAFETY/ 2001/remicade_deardoc.pdf Accessed 10-18-2006.
8. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52: 3403-3412.
9. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumor necrosis factor therapy. Eur J Gastroenterol Hepatol. 2002;14:1393-1395.
10. Gluck T, Linde HJ, Scholmerich J, et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 2002;46:2255-2257.
11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
12. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610.
13. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
14. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722-729.
15. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002; 35: 151-156.
16. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott Raven; 1998:94.
17. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
18. Liddell FD. Simplified exact analysis of case-reference studies: matched pairs; dichotomous exposure. J Epidemiol Community Health. 1983;37:82-84.
19. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1099-1103.
20. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
21. Hommes DW, Oldenberg B, van Bodegraven AA, et al. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med. 2006;64: 219-229.
22. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther. 2006;23:451-463.
23. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?. Gut. 2007;56:1181-1183.
24. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4:1017-1024.
25. Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22:1671-1677.